Calamos Advisors LLC Sells 1,064 Shares of Becton Dickinson and Co (NYSE:BDX)

Calamos Advisors LLC reduced its position in shares of Becton Dickinson and Co (NYSE:BDX) by 1.6% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 64,612 shares of the medical instruments supplier’s stock after selling 1,064 shares during the quarter. Calamos Advisors LLC’s holdings in Becton Dickinson and were worth $17,573,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Allworth Financial LP boosted its position in shares of Becton Dickinson and by 386.4% during the 3rd quarter. Allworth Financial LP now owns 107 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 85 shares during the last quarter. Northwest Investment Counselors LLC purchased a new stake in Becton Dickinson and during the 3rd quarter valued at $27,000. Liberty Wealth Management LLC raised its holdings in Becton Dickinson and by 293.1% during the 3rd quarter. Liberty Wealth Management LLC now owns 114 shares of the medical instruments supplier’s stock valued at $29,000 after buying an additional 85 shares during the period. CX Institutional purchased a new stake in Becton Dickinson and during the 3rd quarter valued at $31,000. Finally, North Star Investment Management Corp. purchased a new stake in Becton Dickinson and during the 3rd quarter valued at $45,000. Hedge funds and other institutional investors own 84.46% of the company’s stock.

NYSE:BDX opened at $277.30 on Thursday. The stock’s fifty day moving average is $267.92 and its 200 day moving average is $256.09. Becton Dickinson and Co has a fifty-two week low of $221.47 and a fifty-two week high of $279.62. The firm has a market capitalization of $74.64 billion, a PE ratio of 23.74, a PEG ratio of 1.97 and a beta of 1.07. The company has a debt-to-equity ratio of 0.86, a quick ratio of 0.72 and a current ratio of 1.18.

Becton Dickinson and (NYSE:BDX) last released its earnings results on Tuesday, November 5th. The medical instruments supplier reported $3.31 earnings per share for the quarter, topping analysts’ consensus estimates of $3.30 by $0.01. Becton Dickinson and had a return on equity of 15.52% and a net margin of 6.84%. The business had revenue of $4.58 billion for the quarter, compared to analyst estimates of $4.57 billion. During the same quarter last year, the firm posted $2.93 earnings per share. The business’s revenue was up 4.1% compared to the same quarter last year. Equities analysts forecast that Becton Dickinson and Co will post 12.57 EPS for the current year.

The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 31st. Shareholders of record on Tuesday, December 10th were paid a $0.79 dividend. This is a positive change from Becton Dickinson and’s previous quarterly dividend of $0.77. The ex-dividend date of this dividend was Monday, December 9th. This represents a $3.16 dividend on an annualized basis and a yield of 1.14%. Becton Dickinson and’s dividend payout ratio (DPR) is presently 27.05%.

In other Becton Dickinson and news, VP Thomas J. Spoerel sold 506 shares of the stock in a transaction on Friday, December 13th. The stock was sold at an average price of $267.95, for a total value of $135,582.70. Following the sale, the vice president now owns 1,035 shares in the company, valued at $277,328.25. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Vincent A. Forlenza sold 13,860 shares of the stock in a transaction on Wednesday, January 8th. The stock was sold at an average price of $275.19, for a total value of $3,814,133.40. Following the completion of the sale, the chief executive officer now owns 227,647 shares in the company, valued at approximately $62,646,177.93. The disclosure for this sale can be found here. In the last quarter, insiders sold 91,231 shares of company stock worth $24,787,690. Insiders own 0.12% of the company’s stock.

Several research firms recently weighed in on BDX. Barclays lowered Becton Dickinson and from an “overweight” rating to an “equal weight” rating and set a $275.00 price target on the stock. in a report on Wednesday, January 8th. Morgan Stanley increased their price target on Becton Dickinson and from $261.00 to $287.00 and gave the company an “equal weight” rating in a report on Tuesday, December 17th. Stifel Nicolaus increased their price target on Becton Dickinson and from $275.00 to $295.00 and gave the company a “buy” rating in a report on Monday, December 16th. KeyCorp decreased their price target on Becton Dickinson and from $262.00 to $256.00 and set an “overweight” rating on the stock in a report on Wednesday, November 13th. Finally, JPMorgan Chase & Co. increased their price target on Becton Dickinson and from $285.00 to $300.00 and gave the company an “overweight” rating in a report on Friday, December 20th. Six research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $277.70.

Becton Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Recommended Story: Is it Safe to Invest in Commodities?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.